SELLAS Life Sciences Announces Additional Positive Triple Negative Breast Cancer (TNBC) Subgroup Data from Phase 2b Study of Nelipepimut-S Plus Trastuzumab  at the 2018 San Antonio Breast Cancer Symposium

World News: . []

NEW YORK Dec 06 2018 GLOBE NEWSWIRE -- SELLAS Life Sciences Group Inc Nasdaq SLS SELLAS or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of can...

More news and information about SELLAS Life Sciences Group

Published By:

Globe Newswire: 13:30 GMT Thursday 6th December 2018

Published: .

Search for other references to "sellas" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us